baber/WOPTO huggingface dataset:
Patent DK-0519463-T3 (DK)
Inventor: PAOLELLA GIOVANNI DR
IPC: C12Q1/68
Filed: 1992-06-17
Granted: 1999-06-28
Abstract: Synthetic catalytic oligonucleotide structure (I) comprising nucleotide units having a hydroxy or alkoxy group in the 2' position, provided that the nucleotide units in the catalytically active center have 2'-hydroxy groups, is new (N.B. it is implied but not stated that the other nucleotide units have 2'-alkoxy groups). Synthetic catalytic oligonucleotide structure (I) comprising at least one nucleotide of formula (II) is new: B' = a nucleobase; V' = O or CH2; X, W' = O, S, NH2, 1-10C alkyl or 1-10C alkoxy; and R = H or 1-10C alkyl; provided that the nucleotides in the catalytically active center have R = H. Independent claims are also included for the following: (1) a method for cleaving a target nucleic acid sequence using (I); (2) a medicament comprising (I) and optionally carriers, excipients, fillers and/or diluents; (3) a diagnostic reagent containing (I) as a component; (4) a catalytic hammerhead oligonucleotide of formula (III); (5) a catalytic hammerhead oligonucleotide of formula (IV); and (6) use of (III) or (IV) to cleave a target nucleic acid sequence of formula (V): N, N0-N14 = nucleotides of formula (II); provided that in; N1, N4, N8, N10 and N11, R = H; and in N2, N3, N5, N6, N7, N9, N12, N13 and N14; R = alkyl; and that N5 and N6 are complementary to each other; x = 1 or more; y = 2 or more; N', N = (a) two nucleotide sequences consisting at least partly of complementary nucleotides to provide stable base pairing between the sequences; or together, N' and N = a single nucleotide sequence, at least part of which can form a double-stranded stem through base pairing of complementary nucleotides; M = a chemical bond or a nucleotide sequence (N)a; a, m, n = 1 or more U = uridine; Z = A, C or U; K, Y = any nucleotides; and b = 3 or more.
Patent DK-0529340-T3 (DK)
Inventor: LERCH DIETMAR
IPC: H04N5/44
Filed: 1992-07-31
Granted: 1997-03-17
Abstract: The invention relates to a method and a device for programme control in television receivers. The invention is based on the fact that television signals which in each case comprise an identification signal designating a particular programme source (for example ARD, ZDF and so forth) are received at the receiving site of a television set. Such an identification signal can be contained, for example, in a colour television signal, particularly in a bi-phase code modulated data block in line 329 of a 625-line standard, or in teletext data which are transmitted jointly with a television signal. According to the invention, possible reflections of the television signal are also taken into consideration in addition to the received field strength during the programme storage, which reflections are detected by means of a comparison of a reference identification signal with the received identification signal. <IMAGE>
Patent DK-0534277-T3 (DK)
Inventor: GLANG SIEGFRIED
IPC: E21D11/38
Filed: 1992-09-15
Granted: 1996-01-22
Abstract: The invention relates to a sealing strip (4) of elastomeric material for tunnel segments (1) provided with an encircling groove (2). The sealing strip (4) has   a) open or closed flutes running on its base side in the longitudinal direction, and   b) channels mostly running likewise in the longitudinal direction. The essential feature of this invention consists in the fact that c) the sealing strip (4) has on its base side at least one retaining foot (5) which runs in a strand shape (i.e. in the longitudinal direction of the strip) and sits in an additional encircling anchoring groove (3).   <IMAGE>
Patent DK-0543195-T3 (DK)
Inventor: ENTIAN KARL-DIETER DR
IPC: C12N15/52
Filed: 1992-10-30
Granted: 1998-09-23
Abstract: Novel recombinant DNA molecule (I) has a sequence corresp. to one or more DNA sequences contd. in a Bgl II fragment of the 54 Rpb episomal element pTii32 from staphylococcus epidermis and codes for at least one protein having EpiB, EpiC, EpiD, EpiP or EpiQ enzymatic activity; or (I) is capable of hybridising to the BglII fragment and codes for at least one protein with the above enzymatic activities. Also claimed are: the protein EpiB, EpiC, EpiD, EpiP or EpiQ in the absence of impurities with which it is normally associated; a fusion protein compising one of EpiB, C, D, P or Q and an auxiliary protein, a fusion protein in which one of the Epi B, C, D, P or Q is fused to an auxiliary protein such that the junction between the Epi protein and the auxiliary protein can be cleaved by an enzyme; and a method of producing a protein with at least one of the structural features of a lantibiotic. In the novel method comprising inserting a DNA sequence coding for a predetermined aminoacid sequence in a vector plasmid such that it is under the control of a regulator promoter, transforming the resulting plasmid vector into a host and cultivating the host so as to express the DNA and isolating the protein, the improvement comprises also transforming the host by a DNA sequence or sequences comprising functionally operable genes coding for EpiB, C, D, P or Q (or an active variant), the genes being expressed during cultivation of the host so that the resulting protein has at least one of the structural features of a lantibiotic.
Patent DK-0500401-T3 (DK)
Inventor: DERIAN PAUL-JOEL
IPC: A01N25/30
Filed: 1992-01-13
Granted: 1999-05-17
Abstract: The present invention relates to novel stable microemulsions of pyrethroid, characterised in that they contain:   - from 0.1% to 95% by weight of at least one pyrethroid in liquid form,   - from 2% to 90% by weight of a surfactant system comprising:     . at least one anionic surfactant,   . at least one non-ionic surfactant,   . at least one cosurfactant selected from among:   + aliphatic alcohols, cycloaliphatic alcohols, arylaliphatic alcohols, ether alcohols and aliphatic carboxylic acids,       - and water, and in that the ratio by weight of anionic surfactant/non-ionic surfactant is from 10/90 to 90/10, and the ratio by weight of cosurfactant/anionic and non-ionic surfactants is from 0.1 to 1.5. Use of the microemulsions, if appropriate after dilution, for the control of insects, in particular in the treatment of crops or for the protection of wood.
Patent DK-0599942-T3 (DK)
Inventor: CLAYTON HEATHER ANNE
IPC: A61K9/50
Filed: 1992-08-14
Granted: 1997-11-03
Abstract: PCT No. PCT/GB92/01511 Sec. 371 Date Jun. 22, 1994 Sec. 102(e) Date Jun. 22, 1994 PCT Filed Aug. 14, 1992 PCT Pub. No. WO93/03710 PCT Pub. Date Mar. 4, 1993.Contaminating protein is removed from a water soluble gum such as alginate by dialyzing a solution of the gum against a solution of a disulphide bond reducing agent. Purifying the gum by removing antigenic protein improves biocompatability of the gum for making biocompatible capsules containing cells such as mammalian cells. The reducing agent is preferably dithiothreitol, dithioerythritol or 2-mercaptoethanol. Dialyzing is preferably carried out for more than 1 hour and more preferably twice, each time for 2 hours. Cells are encapsulated by forming a suspension of cells in an aqueous solution of the gum, forming droplets from the suspension, gelling the droplets with a multivalent cation, contacting the gelled droplets with a polymer containing cationic groups, such as poly-1-lysine chloride, that cross-link with anionic groups of the gum to form a semi-permeable membrane around the droplets, and coating the membrane with a layer of the dialyzed gum. Islets of Langerhans cells can be encapsulated for implanting to produce insulin. In addition to encapsulating cells, the purified gum can be used in making dressings, swabs, sutures, stitches, controlled or sustained release devices and artificial vascular grafts that come in contact with body fluids such as blood.
Patent DK-0590267-T3 (DK)
Inventor: WITTMAN MARK D
IPC: C07C271/22
Filed: 1993-07-30
Granted: 2002-08-19
Abstract: <CHEM>      in which   R<1> is   -COR<z> in which R<z> is RO- or R; R<g> is   C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, or a radical of the formula -W-R<x> in which W is a bond, C2-6 alkenediyl, or -(CH2)t-, in which t is one to six; and R<x> is naphthyl, phenyl, or heteroaryl, and furthermore R<x> can be optionally substituted with one to three same or different C1-6 alkyl, C1-6 alkoxy, halogen or -CF3 groups; R<2> is   -OCOR, H, OH, -OR, -OSO2R, -OCONR<o>R, -OCONHR, -OCOO(CH2)tR, or -OCOOR; and R and R<o>   are independently C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, C2-6 alkynyl, or phenyl, optionally substituted with one to three same or different C1-6 alkyl, C1-6 alkoxy, halogen or -CF3 groups.   Further provided by this invention are pharmaceutical formulations and intermediates for the the preparation of deoxy taxols of formula I. A method of treating mammalian tumors using a compound of formula I is also provided.
Patent DK-0662835-T3 (DK)
Inventor: PIOT FRANCOIS-XAVIER
IPC: A61P31/04
Filed: 1993-09-28
Granted: 1996-12-16
Abstract: New formulations of spiramycin suitable for oral administration, particularly for children, comprise spiramycin and potassium acesulfame. These formulations mask the bitterness of spiramycin without adversely affecting the bioavailability or stability of the spiramycin. Preparation by wet granulation followed by dry state mixing is also disclosed.
Patent DK-0670786-T3 (DK)
Inventor: HEILMANN PETER
IPC: B42D25/29
Filed: 1993-10-16
Granted: 1997-05-05
Abstract: PCT No. PCT/EP93/02860 Sec. 371 Date Feb. 13, 1995 Sec. 102(e) Date Feb. 13, 1995 PCT Filed Oct. 16, 1993 PCT Pub. No. WO94/09990 PCT Pub. Date May 11, 1994An anticopying film or layer consists of a film or of a layer of transparent material having a large number of completely or partially nontransparent regions which are arranged distances apart and whose planes are arranged in about the same predetermined position relative to the surfaces of the film or of the layer so that, from a predetermined viewing angle onto the surfaces of the anticopying film, the latter is essentially transparent. The regions consist at least partially of photosensitive material which is converted by the action of radiation into nontransparent or reflecting material, it also being possible to provide, in the transparent plastics material, furrows or grooves in which the photosensitive material is present.
Patent DK-0624381-T3 (DK)
Inventor: KARPIEL JOHN
IPC: A61M25/06
Filed: 1994-05-13
Granted: 2002-11-18
Abstract: An endoscope having a passage through it is introduced into the mouth of a patient and is guided through the patient's gastroentral tract until an opening at the distal end fo the endoscope is in close proximity with the papilla of water leading to the common bile and pancreatic ducts. A peel-away ERCP catheter is provided which may be guided through the lumen of the endoscope until the distal tip of the catheter emerges from the opening at the distal end of the endoscope. The distal end of the catheter may be guided through the sphincter of oddi and into the common bile or pancreatic duct. A radiopaque dye may be injected through the catheter, into the duct. Additionally, a guide wire may be guided into the common bile or pancreatic duct through the catheter.
Patent DK-0682661-T3 (DK)
Inventor: EVERETT GEORGE S
IPC: C08G2/18
Filed: 1994-01-21
Granted: 2000-04-17
Abstract: Furfuryl alcohol/formaldehyde resins exhibiting high water compatibility and low amounts of volatile organic compounds such as furfuryl alcohol.
Patent DK-0711324-T3 (DK)
Inventor: TOMKA IVAN
IPC: C08L67/04
Filed: 1994-07-14
Granted: 1999-03-22
Abstract: PCT No. PCT/EP94/02321 Sec. 371 Date Jan. 26, 1996 Sec. 102(e) Date Jan. 26, 1996 PCT Filed Jul. 14, 1994 PCT Pub. No. WO95/04106 PCT Pub. Date Feb. 9, 1995In order that a substantially biologically degradable polymer is prevented from at least partially losing its biological degradability when reinforced by additives such as fibers and the like, it is proposed that natural fibers such as, in particular, sisal or ramie fibers, be used.
Patent DK-0671573-T3 (DK)
Inventor: WILKE HERMANN DIPL-ING
IPC: F16H7/06
Filed: 1995-02-10
Granted: 1997-11-03
Abstract: The chain consists of rollers supported by bolts which are linked together by side plates and is driven by a chain wheel. Located next to the chain wheel is a rail (21), held in place in the chain's direction of movement. The plates (15, 16) of the chain are guided and supported in a straight line during the rollers' engagement by two roller tracks (25). The guide rollers (25) are mounted on narrow rails and held by connecting bolts (23) on the wide rail (21). Small chain-guide-rollers are mounted outside the rails on one side of the ends of the chain bolts.
Patent DK-0687730-T3 (DK)
Inventor: KOMARI TOSHIHIKO
IPC: C12N15/74
Filed: 1994-12-06
Granted: 2007-09-17
Abstract: A method of plant transformation whereby a regenerated transgenic plant containing desired genes introduced thereinto is prepared at a high efficiency and which permits the preparation in the subsequent generation of a transgenic plant containing the desired genes but not the drug-resistant genes used as the selection marker. The method comprises transforming a plant by means of agrobacteria and is characterized by cotransforming plant cells with a first T-DNA(1) which functions in plants and contains the drug-resistant genes and a second T-DNA(2) which is contained in the following hybrid vector and contains, inserted therein, desired DNA fragments to be introduced into the plant. The hybrid vector is one prepared by the homologous recombination between the following acceptor vector and the following intermediate vector in agrobacteria. The acceptor vector contains at least (a) a DNA region having the function of plasmid replication which is effective in agrobacteria and colibacilli, (b) a DNA region containing vir B and vir G genes of the virulent region of Ti plasmid pTiBo542 of Agrobacterium tumefaciens, and (c) a DNA region which is homologous with part of the following intermediate vector and is capable of homologous recombination via that part in agrobacteria. The intermediate vector contains at least (i) a DNA region having the function of plasmid replication which is effective in colibacilli but ineffective in agrobacteria, (ii) a DNA region which is homologous with part of the above acceptor vector and is capable of homologous recombination via that part in agrobacteria, and (iii) a DNA region which constitutes at least part of the second T-DNA(2). <IMAGE>
Patent DK-0778781-T3 (DK)
Inventor: KUO JOSEPH S-C
IPC: C07K16/12
Filed: 1995-08-10
Granted: 2001-01-02
Abstract: Immunogenic polysaccharide-protein conjugates are generated which have an oxidized polysaccharide derived from the capsular polysaccharide of Streptococcal pneumniae and the pneumolysin protein of S. pneumoniae which is expressed recombinantly. The pneumolysin is not toxoided prior to conjugation with said oxidized polysaccharide. The immunogenic conjugates are used as vaccines to elicit antibody responses to the capsular polysaccharide of S. pneumoniae and to recombinant pneumolysin, and to immunize against S. pneumoniae-caused disease.
Patent DK-0769569-T3 (DK)
Inventor: REITER ULRICH DR-ING
IPC: C23C8/10
Filed: 1996-10-09
Granted: 2000-06-13
Abstract: Stabilising of an artificial patina on copper sheet comprising applying a clear coat of water glass and hydroxy cellulose immediately after the patina has been produced.
Patent DK-0821755-T3 (DK)
Inventor: KUENZEL HARTWIG
IPC: B32B27/34
Filed: 1996-04-18
Granted: 2001-03-05
Abstract: The invention relates to a vapour barrier for use in the heat insulation of buildings, especially for use in new buildings and the renovation of old ones. The vapour barrier of the invention can effect water vapour exchange in various environmental conditions. This is accomplished by the use as the essential material of a material having a water vapour diffusion resistance depending on the environmental humidity and also had adequate tensile and tear strength.
Patent DK-0835204-T3 (DK)
Inventor: HYSTAD PER
IPC: B63B21/04
Filed: 1996-06-12
Granted: 2001-04-09
Abstract: PCT No. PCT/NO96/00143 Sec. 371 Date Mar. 24, 1998 Sec. 102(e) Date Mar. 24, 1998 PCT Filed Jun. 12, 1996 PCT Pub. No. WO97/00195 PCT Pub. Date Jan. 3, 1997A device involving locking members (4, 5), so-called "flaps", for tow pins on a vessel, e.g., a tugboat, particularly for use with tow lines, towing wire, chains, or the like, where the tow pins are positioned in pairs at the stern of the vessel, optionally capable of being raised and lowered, for guiding the tow line or similar equipment therebetween, where each tow pin in a pair is provided to the top thereof with a respective projecting locking member (4, 5), and where each tow pin (1, 2) is pivotable to permit the locking members (4, 5) to be brought by rotation into locking position by covering the opening between the upper ends of the pins, thereby limiting the vertical movement of the tow line or similar equipment positioned between the tow pins. Each locking member (4, 5) in vertical section and in a transverse direction outward from its respective tow pin (1, 2) has approximately a U-shape. The locking member (4, 5) seen in horizontal plane describes a curve in such manner that said locking members when covering the opening between the tow pins together describe a curve (6) extending in the direction of the vessel stern, and that the U-shaped cross section of the locking member at the part (11) that faces toward the vessel stern has a gently curved form, while the part (12) facing away from the vessel stem has a more upwardly oriented and less pronounced curved form.
Patent DK-0857068-T3 (DK)
Inventor: PRAMOD K SRIVASTAVA
IPC: A61K35/12
Filed: 1996-09-11
Granted: 2004-08-16
Abstract: The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon- alpha , interferon- alpha , interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.
Patent DK-0785412-T3 (DK)
Inventor: WEDEMEYER PETER DIPL-ING VON
IPC: G01C9/26
Filed: 1997-01-15
Granted: 2002-02-25
Abstract: The spirit-level has an elongated housing (1) with conventionally disposed horizontal and vertical levels (2,3) and front and back end covers (4,5). The housing conceals a laser beam generator with a recessed lens (7) and electronic control circuitry. The backlight (11) is incorporated into a slider (9) in the end cover (5). The foresight (10) is a vertical slit in another slider (8) pulled out of the front end cover (4). In its recessed position this slider covers and protects the exit lens.
Patent DK-0837060-T3 (DK)
Inventor: HILPERT HANS
IPC: C07F7/18
Filed: 1997-10-11
Granted: 2001-07-23
Abstract: Preparation of optionally protected 4,8,8-trimethyl-1-oxaspiroÄ2.5Üoct-4-en-6-ol of formula (I) from the protected 4-hydroxy-2,6,6-trimethyl-2-cyclohexen-1-one of formula (II) comprises reaction with a halogenated methyl lithium, followed by optional deprotection. R = H or an OH-protecting group; R' = OH-protecting group.
Patent DK-0886770-T3 (DK)
Inventor: ALBERTINI CARLO
IPC: G01N3/00
Filed: 1997-09-26
Granted: 2002-08-19
Abstract: FIGURE 2 shows compression wave generation apparatus 101 to the left of split Hopkinson pressure bar 102 including input bar 103 connected via test specimen 104 to output bar 105. Compression wave 106,107 is generated by initially placing impactor bar 109 under a pre-load force by hydraulic actuator 108 (in the direction of arrow A) until fragile component 110 ruptures causing end 109a to impact input end 103a of the input bar 103. End 109a is guided and held adjacent end 103a by collar 111 welded to end 109a prevented from movement to the left by blocking system 112. <IMAGE>
Patent DK-0889723-T3 (DK)
Inventor: VON KLEINSORGEN REINHARD
IPC: A61K9/70
Filed: 1997-03-12
Granted: 2002-09-23
Abstract: PCT No. PCT/EP97/01252 Sec. 371 Date Apr. 26, 1999 Sec. 102(e) Date Apr. 26, 1999 PCT Filed Mar. 12, 1997 PCT Pub. No. WO97/35564 PCT Pub. Date Oct. 2, 1997A transdermal therapeutic system for the release of active substances to a substrate is characterized by the structure of the system comprising a substrate (1) provided with a separating layer (2), a film layer (3) comprising the active substance, and a protective layer (4) provided with a nonstick finish, the separating layer (2) consisting of a material whose bond to the film layer (3) may be abolished. By means of printing methods, such systems having small application thickness and high flexibility can be manufactured, it being possible to provide a substrate that has been rendered adhesive as an alternative to the substrate/separating layer-complex. A printing method limiting the active substance-containing region to the application site reduces disposal problems.
Patent DK-0951287-T3 (DK)
Inventor: BUSER THOMAS
IPC: A61K31/606
Filed: 1997-08-12
Granted: 2002-12-09
Abstract: A topical spreadable composition comprising 5-aminosalicylic acid (5-ASA) as active and monoolein is provided for treatment ulcers, inflammation and lesions of the oral cavity. The composition is spread over and adheres to the lesion, and is preferably prepared in a water free state. Examples of indications that can be treated are oral Crohn's Disease, apthous ulcers, orofacial granulomatosis, oral ulcers associated with Behet's disease and oral lichen planus.
Patent DK-0904472-T3 (DK)
Inventor: SCHOFIELD FREDERICK ANDREW
IPC: E04B7/02
Filed: 1997-05-30
Granted: 2002-08-19
Abstract: A building component comprises a cladding unit having an overhang portion and a securing portion. The outer face of the overhang portion serves as a barge/fascia board. The lower face of the overhang portion serves as a soffit. The cladding unit is thin walled and of sideways S-shape with three spaced upright parallel walls. Two walls namely one outer wall and the center wall are connected by a lower plate at their lower edges and form the overhang and two walls namely the center wall and the second outer wall are connected by an upper plate at their upper edges and form the securing portion.
Patent DK-0959730-T3 (DK)
Inventor: HERBST ERIK RIJK ANDRE
IPC: A47C7/02
Filed: 1997-07-16
Granted: 2002-02-18
Abstract: Universal health seat in which the peripheral edge of the top face of the sitting part 5 and the sitting face 4 are formed in such a way that the user thereof receives ideal support. The pelvis of the user is tilted into a correct position by a combination of the position of the recess 6 and the support of the thighs by the peripheral edge of the top face of the sitting part 5. The position of the pelvis affects the curvatures of the spine and consequently the sitting posture of the user. Back complaints are prevented in this way by the universal health seat.